^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations

Published date:
06/12/2020
Excerpt:
Three patients were treated with MEK +/- BRAF inhibitors. Patients harboring G469V and D594G mutations did not respond, while a patient with L597R mutation had durable response.
DOI:
10.1016/j.jtho.2020.05.021